5.7 C
New York
Tuesday, March 5, 2024

J&J’s one-shot Covid vaccine is safe and generates promising immune response in early trial

  • J&J scientists randomly assigned healthy adults between the ages of 18 and 55 and those 65 and older to receive a high or low dose of its vaccine — called Ad26.COV2.S — or a placebo.
  • Most of the volunteers produced detectable neutralizing antibodies, which researchers believe play an important role in defending cells against the virus, after 28 days, according to the trial data.
  • By day 57, all volunteers had detectable antibodies, regardless of vaccine dose or age group, and remained stable for at least 71 days in the 18-to-55 age group.

Related Articles

Latest Articles